본문으로 건너뛰기
← 뒤로

Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.

1/5 보강
Surgical oncology clinics of North America 📖 저널 OA 0% 2023: 0/4 OA 2024: 0/2 OA 2025: 0/1 OA 2026: 0/28 OA 2023~2026 2026 Vol.35(2) p. 399-414
Retraction 확인
출처

Teixeira MF, Fahmy N, Kasi PM

📝 환자 설명용 한 줄

Liquid biopsies offer a promising, noninvasive approach for monitoring and predicting responses to immunotherapy across multiple solid tumors.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Teixeira MF, Fahmy N, Kasi PM (2026). Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.. Surgical oncology clinics of North America, 35(2), 399-414. https://doi.org/10.1016/j.soc.2025.12.010
MLA Teixeira MF, et al.. "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.." Surgical oncology clinics of North America, vol. 35, no. 2, 2026, pp. 399-414.
PMID 41903996 ↗

Abstract

Liquid biopsies offer a promising, noninvasive approach for monitoring and predicting responses to immunotherapy across multiple solid tumors. For the most part these are circulating tumor DNA (ctDNA) based assays. Here, we discuss the biological basis, clinical evidence, and potential applications of different types of ctDNA assays in tracking tumor dynamics, distinguishing pseudoprogression, and assessing minimal residual disease. We explore the current limitations, assay variability, and future directions, including integration with other biomarkers and real-world clinical trials aimed at validating ctDNA as a routine tool in precision immuno-oncology.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반